Authors
Latest:
CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLCSuresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.
Latest:
Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLCSuresh S. Ramalingam, MD, discusses how the EGFR tyrosine kinase inhibitor osimertinib compared with other EGFR inhibitors for patients with EGFR-mutant lung cancer.
Latest:
Discussing Targeted Treatment With PARP Inhibitors for BRCA-Mutant Patients Across Tumor TypesSusan Friedman, executive director and founder, FORCE, a non-profit organization supporting education, advocacy, and research around breast and ovarian cancer, explains the relevance of PARP inhibitors and the recent developments in oncology research that may improve cancer treatment for patients with genetic mutations.
Latest:
AZD9291 in Advanced NSCLCSusan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.
Latest:
Effects of Stress on Ovarian Cancer, Other Cancer TypesSusan Lutgendorf, PhD, professor, Department of Psychological and Brain Sciences, The University of Iowa, discusses a study investigating the effects of stress on immune response and tumor microenvironment in ovarian cancer and other cancer types.
Latest:
The Role of Biomarkers in Patients with Breast CancerSusan M. Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the role biomarkers have in the treatment of patients with breast cancer. Identifying biomarkers in patients early on, such as knowledge of estrogen receptor status, can lead to better treatment plans, Domchek says.
Latest:
Acalabrutinib Plus Obinutuzumab Shows Improved Efficacy in CLLSusan M. O’Brien, MD, discusses the long-term results of the ELEVATE TN trial in patients with previously untreated chronic lymphocytic leukemia.
Latest:
Dr. Susan Panullo on Optune Versus Salvage Chemotherapy in GlioblastomaSusan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A).
Latest:
Cellular Therapy Option for Treatment of Central Nervous System EBV-PTLDSusan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br />
Latest:
Campos Highlights Biggest Advancement in Ovarian Cancer This YearSusana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.
Latest:
<em>ESR1</em> Mutations in Primary Breast CancerSuzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses ESR1 mutations in primary breast cancer.
Latest:
Exploring the Impact of Anti-PD-1 and Anti-PD-L1 Agents in Merkel Cell CarcinomaSuzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses the impact of anti-PD-1 and anti-PD-L1 agents in the treatment of merkel cell carcinoma.
Latest:
Progress in Prostate Cancer Care: Highlights From a Decade of InnovationTargeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.
Latest:
Combination Immunotherapy Appears Promising in Breast Cancer SubtypesSylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
Latest:
Dr. Sylvia Asa on Thyroid Cancer GenotypingDr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Latest:
Dr. Sylvia Asa on Treating Different Types of Thyroid CancerAsa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Latest:
The Importance of Companion DiagnosticsTadd Lazarus, MD, Chief Medical Officer, QIAGEN, discusses the importance of companion diagnostics.
Latest:
The Mechanism of Action of SAR302503Tal Zaks, MD, PhD, explains the mechanism of action of SAR302503, a TKI being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.
Latest:
Dr. Tamar Safra on the Usage of PARP Inhibitors in Gynecological CancersTamar Safra, MD, talks about research into treatments for specific types of ovarian cancer.
Latest:
Dr. Tanguy Seiwert on the Increasing Efficacy of Immunotherapies in Head and Neck CancerSeiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.
Latest:
Treating GVHD in Patients with Myelofibrosis Following TransplantTania Jain, MBBS, discusses the current treatment options for graft-versus-host-disease, a known complication of allogeneic stem cell transplant, which is the only curative treatment option for patients with myelofibrosis.
Latest:
Translating Outcomes in Metastatic Colorectal Cancer (mCRC)In this companion article, Dr Tanios Bekaii-Saab provides insights into effective management of patients with metastatic colorectal cancer.
Latest:
Design and Goals of the Phase 3 MOUNTAINEER-03 Study in mCRCTanios S. Bekaii-Saab, MD, FACP, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study.
Latest:
CAR T-Cell Therapy Shows Promise in the Prostate Cancer SpaceTanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.
Latest:
Acalabrutinib Appears Promising as Monotherapy in CLLTanya Siddiqi, MD, discusses how she sees acalabrutinib fitting into the treatment landscape for patients with chronic lymphocytic leukemia following the results from the phase III ASCEND trial.
Latest:
Dr. Tara Gangadhar on Single-Agent Versus Dual Immunotherapy Approaches in MelanomaGangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.
Latest:
Amorphous Treatment Paradigm in Melanoma Provides Countless OptionsAs new information regarding the efficacy of targeted and immunotherapeutic approaches emerge, the standard of care for patients with melanoma becomes slightly more altered.
Latest:
Next Steps for Novel Treatment Combination in Pancreatic CancerTara Seery, MD, explains the next steps for the QUILT 88 study looking at a novel combination of therapies for patients with metastatic pancreatic cancer.
Latest:
Targeted Oncology™ announces recipients of its Q2 Oncology Icons award programThis award recognizes and celebrates exceptional achievements of individuals whose contributions have significantly influenced the field of oncology.
